ClinicalTrials.gg
RecruitingNCT07019857THYMICUpdated Apr 16, 2026

Impact of Thymectomy on Immunity in Infants After Cardiac Surgery

An interventional study of Blood sample collection at surgery time and 12 months later in Congenital Heart Defects, Thymectomy and Immunological Deficiency Syndrome, sponsored by Nantes University Hospital. Recruiting at 2 sites in France. Open to participants aged Up to 6 Months. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Nantes University Hospital · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
Up to 6 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in Heart Defects, Congenital with a site in France — 19 open to participants now, 22 under way, none of them phase 3. Heart Defects, Congenital · France.

Planned enrollment
20th of 34
70 · median 91
Started
2025
with 9 others
No phase
27 of 73
11 open now
Primary completion
2027-12
later than 13 of 21 live
Registered
68th of 73
by date
Lead sponsor
5 of 73
Nantes University Hospital

Among the 73 studies in Heart Defects, Congenital with a site in France, this one is the 20th largest by planned enrollment of the 34 interventional ones that give a count, is one of 10 that started in 2025, is one of 27 with no phase, reaches primary completion later than 13 of the 21 other live ones, and was the 68th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

19 of the 73 studies in Heart Defects, Congenital with a site in France are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: Up to 6 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Heart Defects, Congenital with a site in France, or all of them as a file.
02

Study summary

Heart surgery in infants typically involves complete removal of the thymus gland to improve access to the heart. However, the thymus plays a key role in developing the immune system in early childhood, especially in the production and maturation of T lymphocytes, which help the body defend itself against infections.

The THYMIC study tests the hypothesis that partial removal of the thymus (partial thymectomy) during heart surgery may better preserve the child's immune function compared to total removal (complete thymectomy). The goal is to determine whether this conservative surgical approach could reduce the risk of immune system impairment and infections in the months following surgery.

This is a prospective, interventional, single-center study conducted at CHU de Nantes, involving 3 groups of infants:

  • One group undergoing heart surgery with complete thymectomy;
  • One group undergoing heart surgery with partial thymectomy;
  • One control group undergoing heart or non-heart surgery without thymus removal. All infants enrolled will have two blood tests: one taken during their surgery and one taken one year later. These blood tests will quantify immune cells (T, B, NK cells), levels of antibodies, and vaccine responses. Parents will also be asked to fill out a questionnaire to record any infections their child experiences during the year after surgery.

By comparing the immune responses and infection rates among the groups, the researchers hope to better understand the long-term effects of thymectomy in infants. The results could support future recommendations to preserve part of the thymus when possible during heart surgery.

Participation in the study does not change the medical or surgical care of the child. The decision to perform a partial or complete thymectomy is made by the surgeon based on the child's anatomy. The additional blood samples are small in volume and follow current safety regulations.

Read the detailed description

The THYMIC study is a prospective, single-center, interventional clinical trial conducted at the University Hospital of Nantes (CHU de Nantes), France. It aims to evaluate the medium-term immunological impact of thymectomy (total versus partial) in infants undergoing cardiac surgery requiring cardiopulmonary bypass (CPB) before the age of 6 months.

Background and Rationale During most pediatric cardiac surgeries, the thymus is completely removed to allow better access to the heart and great vessels. However, the thymus plays a critical role in T-cell development during infancy, contributing to immune system maturation. Prior studies suggest that complete thymectomy in early life may result in persistent alterations in T-cell immunity and increased susceptibility to infections. Yet, the comparative impact of partial versus complete thymectomy on immune function remains poorly studied.

Partial thymectomy is technically feasible in selected cases depending on the anatomy, and could offer a balance between surgical access and immune preservation. The THYMIC study tests the hypothesis that partial thymectomy is associated with less impairment of cellular immunity at 12 months postoperatively and could therefore become the preferred surgical approach in appropriate cases.Study Design

This is a non-randomized, controlled study including 70 infants:

  • 50 infants undergoing cardiac surgery with CPB and either partial or complete thymectomy (surgical decision made

The THYMIC study is a prospective, single-center, interventional clinical trial conducted at the University Hospital of Nantes (CHU de Nantes), France. It aims to evaluate the medium-term immunological impact of thymectomy (total versus partial) in infants undergoing cardiac surgery requiring cardiopulmonary bypass (CPB) before the age of 6 months.

Background and Rationale During most pediatric cardiac surgeries, the thymus is completely removed to allow better access to the heart and great vessels. However, the thymus plays a critical role in T-cell development during infancy, contributing to immune system maturation. Prior studies suggest that complete thymectomy in early life may result in persistent alterations in T-cell immunity and increased susceptibility to infections. Yet, the comparative impact of partial versus complete thymectomy on immune function remains poorly studied.

Partial thymectomy is technically feasible in selected cases depending on the anatomy, and could offer a balance between surgical access and immune preservation. The THYMIC study tests the hypothesis that partial thymectomy is associated with less impairment of cellular immunity at 12 months postoperatively and could therefore become the preferred surgical approach in appropriate cases.

Study Design

This is a non-randomized, controlled study including 70 infants:

  • 50 infants undergoing cardiac surgery with CPB and either partial or complete thymectomy (surgical decision made intraoperatively),
  • 10 infants undergoing cardiac surgery via thoracotomy without thymectomy (control group A),
  • 10 infants undergoing non-cardiac surgery (e.g., digestive surgery) without thymectomy (control group B).

The study involves two blood draws:

  • Baseline (preoperative): performed at anesthesia induction via central catheter (5 mL), including blood cell counts, lymphocyte immunophenotyping, immunoglobulin levels, and TRECs (if Guthrie test not already available).
  • Follow-up (12 months postoperative): peripheral blood draw (5 mL), with repeated immunophenotyping, immunoglobulin levels, and post-vaccine serologies (e.g., diphtheria, tetanus, pneumococcus).

Parents are given a standardized infection monitoring questionnaire at hospital discharge, to be completed with their pediatrician or other care providers over the 12-month follow-up. A phone call is scheduled at 6 months to reinforce compliance. At 12 months, families return for the second blood draw and review of the infection questionnaire. An additional consultation is conducted 15 days later to provide results and arrange follow-up if needed.

Primary Objective To compare cellular immune profiles at 12 months between infants with partial versus complete thymectomy. Key markers include absolute counts of lymphocytes and subsets, and T-cell receptor excision circles (TRECs).

Secondary Objectives

To compare:

  • Humoral immunity markers (B-cell subsets, immunoglobulin levels, vaccine responses),
  • Clinical outcomes such as the number, type, and severity of infections (e.g., hospitalization, ICU admission, antibiotic use) between groups.

Methodology Notes Due to the impossibility of preoperative randomization (surgical decision on thymectomy extent depends on intraoperative anatomy), this is a non-randomized study with group allocation based on surgical findings.

All data are pseudonymized and collected in an electronic case report form (eCRF). Immunological assays are processed via the CHU's certified laboratories (CIMNA platform and hematology department).

Ethical Considerations and Risk-Benefit Assessment The study poses minimal risk. Blood samples are within safe volume limits for infants, and pain is minimized using anesthetic cream and inhaled analgesia (EMLA, MEOPA). Thymectomy extent is based solely on clinical indication and does not depend on study participation. Families benefit from enhanced immunological monitoring, which could identify and help manage acquired immune deficiencies.

Significance This study may provide critical data to support a shift toward more conservative surgical practices regarding thymus preservation in early cardiac surgery, with the potential to reduce long-term immunological sequelae in this vulnerable population.

03

Conditions studied

  • Congenital Heart Defects
  • Thymectomy
  • Immunological Deficiency Syndrome

Keywords

  • Thymectomy
  • Cardiac Surgery
  • Infant
  • Immunity
  • Lymphocytes
  • TRECs
  • Vaccination
  • Infection
04

Who can participate

Ages eligible
Up to 6 Months
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • - Children aged between 0 and 6 months;
  • Born at a gestational age > 37 weeks' gestation;
  • With an indication for cardiac surgery under CEC at Nantes University Hospital;
  • Cardiopediatric follow-up planned at Nantes University Hospital;
  • Written agreement signed by legal guardians to participate in the study.

For the control groups:

  • Control group A (cardiac surgery without thymectomy):

    • Children aged between 0 and 6 months of age;
    • Born at a gestational age > 37 SA;
    • Indicated for thoracotomy cardiac surgery at Nantes University Hospital;
    • Cardiopediatric follow-up planned at Nantes University Hospital;
    • Written agreement signed by legal guardians to participate in the study.
  • Control group B (non-cardiac surgery)

    • Children aged between 0 and 6 months;
    • Born at a gestational age > 37 SA;
    • Indicated for non-cardiac surgery (ENT or visceral surgery at Nantes University Hospital);
    • Planned follow-up surgery at Nantes University Hospital;
    • Written agreement signed by legal guardians to participate in the study.

Exclusion Criteria :

  • Gestational age \< 37 SA;
  • With a history of cardiac surgery under ;
  • And/or with heart disease requiring further surgery within 12 months of the 1st surgery (e.g. pulmonary cerclage, systemic pulmonary anastomosis).
  • And/or a history of partial or complete thymectomy;
  • Receiving long-term treatment;
  • Post-operative follow-up planned in a hospital other than Nantes University Hospital, or moving house planned during the follow-up period;
  • parental refusal.

Exclusion Criteria:

  • - Gestational age \< 37 SA;
  • With a history of cardiac surgery under ECG;
  • And/or with heart disease requiring further surgery within 12 months of the 1st surgery (e.g. pulmonary cerclage, systemic pulmonary anastomosis).
  • And/or a history of partial or complete thymectomy;
  • Receiving long-term immunosuppressive treatment;
  • Post-operative follow-up planned in a hospital other than Nantes University Hospital, or moving house planned during the follow-up period;
  • parental refusal.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Complete Thymectomy Group

    Infants undergoing cardiac surgery with cardiopulmonary bypass (CPB), during which a complete thymectomy is performed for surgical access to the heart and great vessels. The extent of thymus resection is determined by the cardiac surgeon intraoperatively, based on anatomical considerations

    Diagnostic Test: Blood sample collection at surgery time and 12 months later

  • Experimental
    Partial Thymectomy Group

    Infants undergoing cardiac surgery with CPB, during which a partial thymectomy is performed, with an effort to preserve thymic tissue when anatomically feasible.

    Diagnostic Test: Blood sample collection at surgery time and 12 months later

  • Active comparator
    Control Group (No Thymectomy

    Infants undergoing: * Cardiac surgery by thoracotomy without thymectomy (e.g., for aortic coarctation) or * Non-cardiac surgery (e.g., digestive procedures) with complete preservation of the thymus. These patients serve as immunological reference controls

    Diagnostic Test: Blood sample collection at surgery time and 12 months later

Interventions

  • Diagnostic testBlood sample collection at surgery time and 12 months later

    each participant undergoes a blood test 1) at surgery time and 2) 12 months after surgery. These 5mL samples include: * Blood cell count * TREC dosage * Complete Lymphocytes immunophenotyping * Immunoglobulin dosage

06

What researchers measure

Primary outcomes

  1. T-Lymphocyte response

    biological endpoint with absolute quantification of LyTs, LyT subpopulations and TRECs.

    Time frame: 12 months after surgery

Secondary outcomes

  1. Humoral response

    absolute quantification of LyB, weighted immunoglobulin assays and post-vaccination serologies

    Time frame: 12 months after surgery

  2. Clinical impact

    the number of infectious episodes, their severity as assessed by the need for hospitalisation, the number of days spent in intensive care, the number of days on antibiotics, etc.

    Time frame: 12 months after surgery

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 28 months after the start.

Of 208 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 28 months is below that.

Counting every sponsor, half of 226 studies reached it within 34 months; a quarter within 17 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jun 13, 2025
StartActual
Jul 25, 2025
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07019857
Responsible party
Sponsor
First posted
Jun 13, 2025
Start date
Jul 25, 2025
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Apr 16, 2026

Study contacts

Alexis Chenouard, PH
Contact
alexis.chenouard@chu-nantes.fr
02 44 76 82 21
Evelyne Gauvard
Contact
Evelyne.GAUVARD@chu-nantes.fr
Alexis Chenouard, PH
principal investigator · Nantes University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion